Description
Latin name
Betaserc
Release form
Tablets.
packaging 20 pcs
Pharmacological action
Betaserc – improves microcirculation.
Pharmacodynamics
Betaserc (betahistine) acts primarily on the histamine H1 and H3 receptors of the inner ear and vestibular nuclei of the central nervous system. By direct agonistic action on the H1 receptors of the vessels of the inner ear, as well as indirectly through the action on the H3 receptors, it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea. However, betahistine increases blood flow in the basilar arteries. Betaserk ® also has a pronounced central effect due to the influence of the vestibular nerve nuclei on the H3 receptors. Normalizes the conductivity in neurons of the vestibular nuclei at the level of the brain stem. A clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing if it is reduced.
Indications
vestibular dizziness
syndromes characterized by dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting
disease / Meniere’s syndrome.
Contraindications
hypersensitivity to any of the components of the drug
pheochromocytoma
gastric ulcer and duodenal ulcer in the acute phase.
Use during pregnancy and lactation
There is insufficient data on the use of betahistine in pregnant women. The potential risk to humans is unknown. Betagistin should not be used during pregnancy unless absolutely necessary.
It is not known whether betahistine and breast milk are excreted. You should not prescribe the drug during breastfeeding. The question of the appointment of Betaserk ® mother should be taken only after comparing the benefits of breastfeeding with the potential risk to the infant.
Composition
1 tablet contains:
Active ingredient: betahistine dihydrochloride – 24 mg.
Excipients: microcrystalline cellulose – 242 mg, mannitol (E421) – 75 mg, citric acid monohydrate – 7.5 mg, colloidal silicon dioxide – 7.5 mg, talc – 19 mg.
Dosage and administration of
The drug is administered orally with food. The dose should be selected individually depending on the response to treatment.
For adults, the dose is 24-48 mg / day.
Dose / frequency of administration:
Betaserc ® 8 mg – 1-2 tablets 3 times a day.
Betaserc ® 16 mg – 1 / 2-1 tablets 3 times a day.
Betaserc ® 24 mg – 1 tablet 2 times a day.
16 mg tablet and 24 mg tablet can be divided into 2 equal parts. To do this, place the tablet on a hard surface with the scuff up and press on it with your thumb.
Improvement is sometimes observed only after a few weeks of treatment, and a stable therapeutic effect after several months of treatment. There is evidence that the appointment of the drug at the beginning of the disease prevents its progression and / or hearing loss in later stages.
Despite the limited clinical trial data, extensive post-registration experience suggests that dose adjustment in elderly patients is not required.
No specific clinical studies have been conducted in patients with renal and / or liver failure, however post-registration experience suggests that dose adjustment in this group of patients is not required.
Side effects
Gastrointestinal upsets (nausea, feeling of heaviness in the epigastrium) are possible, which can be prevented by taking the drug after meals or by reducing the dose. In very rare cases, the appearance of hypersensitivity reactions from the skin, in particular, skin rash, itching and urticaria, has been reported.
Drug Interaction
No data available.
overdose
Symptoms: mild and moderate nausea, drowsiness, abdominal pain were observed in some patients after up to 640 mg doses. More serious complications (convulsions, cardiopulmonary complications) were observed with the intentional administration of betahistine in high doses, especially in combination with an overdose of other drugs.
Treatment: carrying out symptomatic therapy.
Storage conditions
The drug should be stored out of the reach of children, in a dry place at a temperature not exceeding 25 ° C.
Expiration
5 Chron
Deystvuyuschee substances
betahistine
pharmacy leave terms
dosage form
Dosage form
tablets
